Status:
RECRUITING
Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Medical Center Haaglanden
Leiden University Medical Center
Conditions:
Glioma
Radiotherapy; Complications
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with...
Detailed Description
Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro and UMC Groningen and referred Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC, Verbeeten Institute, Maastro...
Eligibility Criteria
Inclusion
- Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
- Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
- Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
- Age ≥ 18 years
Exclusion
- Prior cranial radiotherapy
- Contra-indication for MRI imaging
- Chemotherapy delivered before radiotherapy
- Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3)
- Combination photon and proton therapy
- Patient has previously opted-out of the use of their data for research
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT06180434
Start Date
May 1 2024
End Date
November 1 2025
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, Netherlands